Autopsy report · NCT05943990
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Cause of deathFunding or business
“The study was terminated due to a change in GSK's R\&D priorities.”
Life of this trial
- Registered 2 years 6 months after it had already started.
- Ran for about 1 year 10 months before it stopped.
- 5 participants enrolled.
- Results were posted on the registry 1 year 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Adaptimmune
- Sponsor type
- Industry
- Conditions
- Neoplasms
- Interventions
- GSK3845097; Cyclophosphamide; Fludarabine
- Participants
- 5
- Sites
- 21
- Countries
- Australia, Canada, Germany, Netherlands, Sweden, United States
Trials that died the same way
- Randomized Controlled Study to Incentivize Doctors for Appropriate Use of Medical Care in NL
“The study was terminated due to logistical reasons” - Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis
“Study was prematurely discontinued due to GSK's change in prioritization for the portfolio and is not due to any safety concerns or regulatory interaction.” - Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
“The study was terminated due to low accrual.” - Therapeutic Exercise in Patients With Hemophilia
“The Study was terminated due to lack of funding for continuing” - An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections
“Study was prematurely terminated due to administrative and strategic reasons”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.